178 related articles for article (PubMed ID: 30831507)
21. [Population study of dihydropyrimidine dehydrogenase in cancer patients].
Etienne MC; Milano G; Renée N; Lagrange JL; Dassonville O; Thyss A; Schneider M; François E; Fleming R; Demard F
Bull Cancer; 1995 Sep; 82(9):705-10. PubMed ID: 8535028
[TBL] [Abstract][Full Text] [Related]
22. Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
Lee A; Ezzeldin H; Fourie J; Diasio R
Clin Adv Hematol Oncol; 2004 Aug; 2(8):527-32. PubMed ID: 16163233
[TBL] [Abstract][Full Text] [Related]
23. Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients.
Katona C; Kralovánszky J; Rosta A; Pandi E; Fónyad G; Tóth K; Jeney A
Oncology; 1998; 55(5):468-74. PubMed ID: 9732227
[TBL] [Abstract][Full Text] [Related]
24. Population study of dihydropyrimidine dehydrogenase in cancer patients.
Etienne MC; Lagrange JL; Dassonville O; Fleming R; Thyss A; Renée N; Schneider M; Demard F; Milano G
J Clin Oncol; 1994 Nov; 12(11):2248-53. PubMed ID: 7964939
[TBL] [Abstract][Full Text] [Related]
25. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
26. 5-Fluorouracil Chemotherapy for Dihydropyrimidine Dehydrogenase-deficient Patients: Potential of the Dose-escalation Method.
Yoshida Y; Ogura K; Hiratsuka A; Aisu N; Yamada T; Kojima D; Tanimura S; Ogata K; Hara S; Mogi A; Takamatsu Y; Tamura K; Mishima H; Yamashita Y
Anticancer Res; 2015 Sep; 35(9):4881-7. PubMed ID: 26254383
[TBL] [Abstract][Full Text] [Related]
27. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
Zhou ZW; Wang GQ; Wan DS; Pan ZZ; Li S; Chen G; Liao H
Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669
[TBL] [Abstract][Full Text] [Related]
28. Prompt treatment with uridine triacetate improves survival and reduces toxicity due to fluorouracil and capecitabine overdose or dihydropyrimidine dehydrogenase deficiency.
Garcia RAG; Saydoff JA; Bamat MK; von Borstel RW
Toxicol Appl Pharmacol; 2018 Aug; 353():67-73. PubMed ID: 29908244
[TBL] [Abstract][Full Text] [Related]
29. Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency.
Gbeto CC; Quaranta S; Mari R; Fanciullino R; Roche C; Nahon S; Solas C; Ouafik L; Lacarelle B; Allegre T; Ciccolini J
Pharmacogenomics; 2019 Aug; 20(13):931-938. PubMed ID: 31486738
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
Raida M; Schwabe W; Häusler P; Van Kuilenburg AB; Van Gennip AH; Behnke D; Höffken K
Clin Cancer Res; 2001 Sep; 7(9):2832-9. PubMed ID: 11555601
[TBL] [Abstract][Full Text] [Related]
31. [Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients].
Peng RJ; Dong QM; Shi YX; Cao Y; Zhou ZM; Yuan ZY; Li S; Li H; Jiang WQ
Ai Zheng; 2006 Aug; 25(8):1039-43. PubMed ID: 16965690
[TBL] [Abstract][Full Text] [Related]
32. Impact of Guidelines Regarding Dihydropyrimidine Dehydrogenase (DPD) Deficiency Screening Using Uracil-Based Phenotyping on the Reduction of Severe Side Effect of 5-Fluorouracil-Based Chemotherapy: A Propension Score Analysis.
Laures N; Konecki C; Brugel M; Giffard AL; Abdelli N; Botsen D; Carlier C; Gozalo C; Feliu C; Slimano F; Djerada Z; Bouché O
Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297556
[TBL] [Abstract][Full Text] [Related]
33. Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil (review).
Milano G; Etienne MC
Anticancer Res; 1994; 14(6A):2295-7. PubMed ID: 7825962
[TBL] [Abstract][Full Text] [Related]
34. Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen?
Vogel WH; Minhas A; Baumrucker S
J Adv Pract Oncol; 2020; 11(1):68-73. PubMed ID: 33542850
[TBL] [Abstract][Full Text] [Related]
35. DPYD*2A mutation: the most common mutation associated with DPD deficiency.
Saif MW; Ezzeldin H; Vance K; Sellers S; Diasio RB
Cancer Chemother Pharmacol; 2007 Sep; 60(4):503-7. PubMed ID: 17165084
[TBL] [Abstract][Full Text] [Related]
36. The Evaluation of Dihydropyrimidine Dehydrogenase Enzyme Level in the Serum of Colorectal Cancer Iraqi Males on Fluoropyrimidine-Based Chemotherapy (Capecitabine).
Challoob MA; Mohammed NS
Cureus; 2023 Sep; 15(9):e44534. PubMed ID: 37790008
[TBL] [Abstract][Full Text] [Related]
37. Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency.
Schmitt A; Royer B; Boidot R; Berthier J; Ghiringhelli F
Front Oncol; 2023; 13():1187052. PubMed ID: 37409256
[TBL] [Abstract][Full Text] [Related]
38. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
van Kuilenburg AB
Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568
[TBL] [Abstract][Full Text] [Related]
39. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
Ogura K
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency.
van Staveren MC; Guchelaar HJ; van Kuilenburg AB; Gelderblom H; Maring JG
Pharmacogenomics J; 2013 Oct; 13(5):389-95. PubMed ID: 23856855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
